DocGo Q3 adjusted EBITDA beats analyst expectations on  business lines restructuring

By Reuters News


Overview

  • US mobile health and transport firm's Q3 revenue rose yr/yr but missed analyst expectations

  • Q3 adjusted EBITDA loss narrowed and beat analyst expectations

  • Gross margin improved 280 bps over Q2 driven by profitability initiatives


Outlook

  • Company lowers full-year 2026 revenue outlook to $300 mln from $305-$310 mln

  • Company maintains full-year 2026 adjusted EBITDA guidance at ($17)-($22) mln

  • Company expects improved margins and increased volumes as patient outreach ramps up


Result Drivers

  • BUSINESS LINE RESTRUCTURING - Co said elimination and restructuring of unprofitable business lines drove improved margins and narrowed adjusted EBITDA loss

  • COST OPTIMIZATION - Co attributed margin improvement to profitability initiatives, including cost controls, despite higher fuel costs

  • VOLUME GROWTH IN CORE SEGMENTS - Co reported record volumes in medical transportation, mobile phlebotomy, and remote monitoring


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$73.4 mln

$77.19 mln (5 Analysts)

Q3 Net Loss

$18.29 mln

Q3 Adjusted EBITDA

Beat

-$3.2 mln

-$4.43 mln (5 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for DocGo Inc. is $1.75, about 614.3% above its November 6 closing price of $0.25


Reuters Recommended Reads

  • Nov 9 - Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion

  • Nov 8 - RadNet beats Q3 adjusted EPS estimates, lifts 2026 outlook

  • Nov 9 - US FDA orders new eye risk warnings for Ozempic, Zepbound


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.